Abstract Improving outcomes for high-risk acute lymphoblastic leukaemia (ALL) patients requires increasingly personalized treatment strategies that leverage molecular and omics-based assays as well as functional screens. However, to date, only a few of these approaches are clinically actionable and easily adopted in clinical settings. To that end, we report a combination drug screening assay (GradientScreen) that correlates with clinical outcomes using standard paediatric ALL treatment protocols.
